IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash: preclinical and clinical responses

作者：Yuli Ruan, Mengde Shi, Yue Ma, Bojun Wang, Ming Ma, Tianjiao Dang, Yanqiao Zhang, Chao Liu · 发表于：Cancer Biology and Medicine · 年份：2025 · DOI：10.20892/j.issn.2095-3941.2025.0344 · 被引用次数：1 · 研究领域：Cancer Immunotherapy and Biomarkers、Psoriasis: Treatment and Pathogenesis、Immunodeficiency and Autoimmune Disorders

Psoriasiform rash is a notable immune-related cutaneous adverse event (ircAE) accounting for approximately 5% of all ircAEs[1][1],[2][2]. Patients with cancer and pre-existing psoriasis face elevated risk of disease recurrence or exacerbation after receiving immune checkpoint inhibitors (ICIs). A